Partial tolerance of subcutaneously transplanted xenogeneic tumour cell graft by Fas-mediated immunosuppression

Immunology

Volumn 103, Issue 1, 2001, Pages 81-89

  Sawada, Takahiro ^a   Kishimoto, Koji ^a   Nagayasu, Takeshi ^a   Takahashi, Takao ^a   Oka, Tadayuki ^a   Ayabe, Hiroyoshi ^a   Koji, Takehiko ^a   Hishikawa, Yoshitaka ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIBODY; FAS ANTIGEN; IMMUNOGLOBULIN G; LIPOCORTIN 5;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CELLULAR IMMUNITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MALE; NATURAL KILLER CELL; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL; TUMOR GROWTH; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD95; ANTIGENS, NEOPLASM; APOPTOSIS; GRAFT SURVIVAL; IMMUNOSUPPRESSION; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; LYMPHOCYTE CULTURE TEST, MIXED; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; SPLEEN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0034996614     PISSN: 00192805     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2567.2001.01223.x     Document Type: Article

References (34)

1. Lawson JH, Platt JL. Molecular barriers to xenotransplantation. Transplantation 1996; 62:303-10.
2. Pierson RN, III, Winn HJ, Russell PS, Auchincloss H Jr. Xenogeneic skin graft rejection is especially dependent on CD4+ T cells. J Exp Med 1989; 170:991-6.
3. Faustman D, Coe C. Prevention of xenograft rejection by masking donor HLA class I antigens. Science 1991; 252:1700-2.
4. Lin Y, Goebels J, Xia G, Ji P, Vandeputte M, Waer M. Induction of specific transplantation tolerance across xenogeneic barriers in the T independent immune compartment. Nat Med 1998; 4:173-80.
5. Smyth MJ, Kershaw MH, Trapani JA. Xenospecific cytotoxic T lymphocytes. Transplantation 1997; 63:1171-98.
6. Trauth BC, Klas C, Peters AMJ, Matzku S, Moller P, Falk W, Debatin KM, Krammer PH. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989; 245: 301-5.
7. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989; 169:1747-56.
8. Hakuno N, Koji T, Yano T, Kobayashi N, Tsutsumi O, Taketani Y, Nakane PK. Fas/Apo-1/CD95 system as a mediator of granulosa cell apoptosis in ovarian follicle atresia. Endocrinology 1996; 137:1938-48.
9. Tamura M, Kimura H, Koji T et al. Role of apoptosis of thyrocytes in a rat model of goiter. A possible involvement of Fas system. Endocrinology 1998; 139:3646-53.
10. Nogae S, Miyazaki M, Kobayashi N et al. Induction of apoptosis in ischemia-reperfusion model of mouse kidney: possible involvement of Fas. J Am Soc Nephrol 1998; 9:620-53.
11. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75:1169-98.
12. Ju S, Panka DJ, Cui H et al. Fas (CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature 1995; 373:444-8.
13. Renno T, Hahne M, Tschopp J, MacDonald HR. Peripheral T cells undergoing superantigen-induced apoptosis in vivo express B220 and upregulate Fas and Fas ligand. J Exp Med 1996; 183: 431-7.
14. Selawry H, Fajaco R, Whittington K. Intratesticular islet allografts in the spontaneously diabetic BB/W rat. Diabetes 1985; 34:1019-24.
15. Bobzien B, Yasunami Y, Majercik M, Lacy PE, Davie JM. Intratesticular transplants of islet xenografts (rat to mouse). Diabetes 1983; 32:213-6.
16. Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270:1189-92.
17. Ferguson TA, Griffith TS. A vision of cell death: insights into immune privilege. Immunol Rev 1997; 156:167-84.
18. Lau HT, Yu M, Fontana A, Stoeckert CJ Jr. Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice. Science 1996; 273:109-12.
19. Fujihara K, Goldman B, Oseroff AR, Glenister N, Jaffe ES, Bisaccia E, Pincus S, Greenberg SJ. HTLV-associated disease: human retroviral infection and cutaneous T-cell lymphomas. Immunol Invest 1997; 26:231-42.
20. Nagatani T, Miyazawa M, Matsuzaki T et al. Adult T-cell leukemia with predominant skin involvement. Int J Dermatol 1998; 37: 275-91.
21. Okumura C, Suto R, Furukawa K, Ahmed SS, Furukawa K, Nakayama E, Fujii T, Shiku H. Induction of murine γδ T cells cytotoxic for xenogeneic rat cells. J Immunolimmunol 1995; 154:1114-23.
22. Nishimura Y, Ishii A, Kobayashi Y, Yamasaki Y, Yonehara S. Expression and function of mouse Fas antigen on immature and mature T cells. J Immunol 1995; 154;4395-453.
23. Koji T, Kobayashi N, Nakanishi Y et al. Immunohistochemical localization of Fas antigen in paraffin sections with rabbit anti-bodies against human synthetic Fas peptides, Acta Histochem Cytochem 1994; 27:459-63.
24. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119:493-501.
25. Hashimoto S, Koji T, Niu J, Kanematu T, Nakane PK. Differential staining of DNA strand breaks in dying cells by non-radioactive in situ nick translation. Arch Histol Cytol 1995; 58:161-90.
26. Azuma T, Sato S, Kitagawa S, Hori S, Kokudo S, Hamaoka T, Fujiwara H. Tolerance induction of allo-class I H-2 antigen-reactive Lyt-2+ helper T cells and prolonged survival of the corresponding class I H-2-disparate skin graft. J Immunol 1989; 143:1-8.
27. Kitagawa S, Sato S, Azuma T, Shimizu J, Hamaoka T, Fujiwara H. Heterogeneity of CD4+ T cells involved in anti-allo-class I H-2 immune responses, J Immunol 1991; 146:2513-21.
28. Nakayama E, Shiku H, Takahashi T, Oettgen HF, Old LJ. Definition of a unique cell surface antigen of mouse leukemia RL♂1 by cell-mediated cytotoxicity. Proc Natl Acad Sci USA 1979; 76:3486-90.
29. Yagita H, Seino K, Kayagaki N, Okumura K. CD95 ligand in graft rejection. Nature 1996; 379:682-3.
30. Tsubata T, Wu J, Honjo T. B-cell apoptosis induced by antigen receptor crosslinking is blocked by a T-cell signal through CD40. Nature 1993; 364:645-8.
31. Parry SL, Hasbold J, Holman M, Klaus GGB, Hypercross-linking surface IgM or IgD receptors on mature B cells induces apoptosis that is reversed by costimulation with IL-4 and anti-CD40. J Immunol 1994; 152:2821-9.
32. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. Expansion or elimination of B cells in vivo: dual roles for CD40- and Fas (CD95) -ligands modulated by the B cell antigen receptor. Cell 1996; 87:319-29.
33. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L; CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest 1998; 102:473-82.
34. Ogasawara J, Watanabe-Fukunaga R, Adachi M et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993; 364:806-17.